Related Experiment Video
Updated: Jan 29, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Trop-2.2-Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Edwin C Pratt1, David Bauer1, Lukas M Carter1
1Molecular Pharmacology Department, Memorial Sloan Kettering Cancer Center, New York, New York.
This study repurposes a Trop-2.2 antibody for targeted cancer radiotherapies, demonstrating therapeutic benefits in a pancreatic cancer model. Pretargeted strategies and fractionated dosing show promise for improved efficacy and reduced toxicity.
Area of Science:
- Oncology
- Radiopharmaceutical Therapy
- Molecular Imaging
Background:
- Trophoblast cell surface antigen-2 (Trop-2) is linked to cancer invasiveness and poor outcomes.
- Current antibody-drug conjugate therapy lacks patient selection based on Trop-2 expression, risking adverse effects.
- A theranostic approach using Trop-2 targeting can improve patient and therapy selection.
Purpose of the Study:
- To repurpose the Trop-2.2 antibody for targeted radiotherapies using Lutetium-177, Actinium-225, and Lead-212.
- To evaluate different radiopharmaceutical dosing strategies, including direct, tandem, pretargeted, and fractionated approaches.
- To assess the therapeutic efficacy and toxicity of these novel radiopharmaceutical variants in a Trop-2 expressing cancer model.
Main Methods:
- Repurposing the Trop-2.2 antibody for conjugation with various radioisotopes (Lu-177, Ac-225, Pb-212).
- Investigating direct, tandem, pretargeted, and fractionated dosing strategies for radiopharmaceutical delivery.
- Evaluating tumor regression, survival rates, and specific organ toxicities (renal, ovarian) in a preclinical cancer model.
Main Results:
- Actinium-225 therapy demonstrated significant tumor regression and improved survival in mice.
- Lead-212 was more effective with a pretargeting strategy than direct labeling.
- Fractionated Lead-212 dosing showed sustained tumor reduction with manageable toxicity, though renal and ovarian toxicity were observed with repeat administrations.
Conclusions:
- Direct and pretargeted radiopharmaceutical variants targeting Trop-2.2 offer therapeutic benefits.
- Pretargeting strategies and fractionated dosing show potential for optimized cancer radiotreatment.
- This work supports the theranostic potential of Trop-2.2 targeting for personalized cancer therapy.
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Directing Effect of Substituents: meta-Directing Groups
Directing Effect of Substituents: ortho–para-Directing Groups
Pancreatic Juice and Secretion
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

